Cancer Research Advances Regarding the CKLF-like MARVEL Transmembrane Domain Containing Family

  • Lu, Jia (School of Basic Medical, The Fourth Hospital of Hebei Medical University) ;
  • Wu, Qian-Qian (School of Stomatology, The Fourth Hospital of Hebei Medical University) ;
  • Zhou, Ya-Bo (School of Public Health, The Fourth Hospital of Hebei Medical University) ;
  • Zhang, Kai-Hua (School of Basic Medical, The Fourth Hospital of Hebei Medical University) ;
  • Pang, Bing-Xin (School of Basic Medical, The Fourth Hospital of Hebei Medical University) ;
  • Li, Liang (School of Basic Medical, The Fourth Hospital of Hebei Medical University) ;
  • Sun, Nan (Department of Blood Transfusion, The Fourth Hospital of Hebei Medical University) ;
  • Wang, Heng-Shu (Department of Pathology, The Second Hospital of Hebei Medical University) ;
  • Zhang, Song (Department of Clinical Laboratory, The Third Affiliated Hospital) ;
  • Li, Wen-Jian (Department of Immunology, Hebei Medical University) ;
  • Zheng, Wei (Department of Surgical Oncology, Chinese PLA General Hospital) ;
  • Liu, Wei (Department of Immunology, Hebei Medical University)
  • Published : 2016.06.01

Abstract

The CKLF-like MARVEL transmembrane domain-containing family (CMTM) is a novel family of genes first reported at international level by Peking University Human Disease Gene Research Center. The gene products act between chemokines and the transmembrane-4 superfamily. Located in several human chromosomes, the CMTMs CKLF and CMTM1 to CMTM8 may be unregulated in tumors and act as potential tumor suppressor genes with important roles in the immune, male reproductive and hematopoietic systems. In-depth studies in recent years established a close relation between CMTMs and tumorigenesis and metastasis. The CMTM family has a significant clinical value in diagnosis and treatment of diseases linked to tumors and the immune system.

Keywords

CMTM family;gene;chemokine-like factor;tumor;diagnosis;treatment

References

  1. Bu L, Jiang G, Wang J (2008). Expression of cklf1,cmtm1, cmtm2 and cmtm4 in non-small cell lung cancer. Chinese J Exp Surg, 25, 1126-7 [in Chinese].
  2. Chen S, Du Y, Huang Y, Wang X, GU Q, Dong Z (2007). Effects of novel human chemokine-like factor superfamily 8 on proliferation and egfr expression of hl-60 cells. J Exp Hematol, 15, 458-61 [in Chinese].
  3. Gao D, Hu H, et al (2015). CMTM8 inhibits the carcinogenesis and progression of bladder cancer. Oncol Rep, 34, 2853-63. https://doi.org/10.3892/or.2015.4310
  4. Han W, Ding P, Xu M, et al (2003). Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics, 81, 609-17. https://doi.org/10.1016/S0888-7543(03)00095-8
  5. Han W, Lou Y, Tang J, et al (2001). Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J, 357, 127-35. https://doi.org/10.1042/bj3570127
  6. Harris SL, Thorne LB, Seaman WT, Hayes DN, Couch ME and Kimple RJ (2011): Association of p16 (INK4a) overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue. Head Neck, 33, 1622-7. https://doi.org/10.1002/hed.21650
  7. Li H, Li J, Su Y, et al (2014). A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growth. Oncogene, 33, 3109-18. https://doi.org/10.1038/onc.2013.282
  8. Li P, Liu K, Li L, et al (2011). Reduced CMTM5 expression correlates with carcinogenesis in human epithelial ovarian cancer. Int J Gynecological Cancer, 21, 1248-55.
  9. Li T, Cheng Y, et al (2015). CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma. J Exp Clin Cancer Res, 16, 34-122.
  10. Li Z, Xie J, Wu J, et al (2014). CMTM3 inhibits human testicular cancer cell growth through inducing cell-cycle arrest and apoptosis. PloS one, 9, 88965. https://doi.org/10.1371/journal.pone.0088965
  11. Liu B, Su Y, et al (2015). CMTM7 knockdown increases tumorigenicity of human non-small cell lung cancer cells and EGFR-AKT signaling by reducing Rab5 activation. Oncotarget, 6, 41092-107. https://doi.org/10.18632/oncotarget.5732
  12. Liu Q, Su Y, Jiang GC, et al (2013). Change of CMTM7 expression, a potential tumor suppressor, is associated with poor clinical outcome in human non-small cell lung cancer. Chinese Med J, 126, 3006-12.
  13. Miyazaki A, Yogosawa S, Murakami A and Kitamura D (2012). Identification of CMTM7 as a transmembrane linker of BLNK and the B-cell receptor. PloS one, 7, 31829. https://doi.org/10.1371/journal.pone.0031829
  14. Morrison AC, Felix JF, Cupples LA, et al (2010). Genomic variation associated with mortality among adults of European and African ancestry with heart failure: the cohorts for heart and aging research in genomic epidemiology consortium. Circulation. Cardiovascular Genetics, 3, 248-55. https://doi.org/10.1161/CIRCGENETICS.109.895995
  15. Peng C, Guan-chao J and Jun W (2009). CMTM4 and CMTM8 expression in esophageal and cardiac carcinoma. Shandong Medical Journal, 6, 21-22 [in Chinese].
  16. Plate M, Li T, Wang Y, et al (2010). Identification and characterization of CMTM4, a novel gene with inhibitory effects on HeLa cell growth through Inducing G2/M phase accumulation. Molecules Cells, 29, 355-361. https://doi.org/10.1007/s10059-010-0038-7
  17. Su Y, Lin Y, Zhang L, et al (2014). CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer. Cancer Sci, 105, 26-34. https://doi.org/10.1111/cas.12304
  18. Wang Y, Li J, Cui Y, et al (2009). CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res, 69, 5194-201. https://doi.org/10.1158/0008-5472.CAN-08-3694
  19. Xiao Y, Yuan Y,et al (2015). CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo. Clin Transl Oncol, 17, 431-7. https://doi.org/10.1007/s12094-014-1253-z
  20. Xie J, Yuan Y, Liu Z, et al (2014). CMTM3 is frequently reduced in clear cell renal cell carcinoma and exhibits tumor suppressor activities. Clinical Translational Oncol, 16, 402-9. https://doi.org/10.1007/s12094-013-1092-3
  21. Yang GY, Chen X, Sun YC, Ma CL, Qian G (2013). Chemokinelike factor 1 (CLFK1) is over-expressed in patients with atopic dermatitis. Int J Biological Sci, 9, 759-65. https://doi.org/10.7150/ijbs.6291
  22. Zhang H, Nan X, Li X, et al (2014). CMTM5 exhibits tumor suppressor activity through promoter methylation in oral squamous cell carcinoma. Biochem Biophys Res Commun, 447, 304-10. https://doi.org/10.1016/j.bbrc.2014.03.158
  23. Zhang H, Zhang J, Nan X, et al (2015). CMTM3 inhibits cell growth and migration and predicts favorable survival in oral squamous cell carcinoma. Tumour Biol, 36, 7849-58. https://doi.org/10.1007/s13277-015-3504-1
  24. Zhang S, Pei X, Hu H, et al (2015). Functional characterization of the tumor suppressor CMTM8 and its association with prognosis in bladder cancer. Tumour Biol, 37, 6217-25..
  25. Zhang Y, Wang JY and Han W (2014). A role for CMTM7 in BCR expression and survival in B-1a but not B-2 cells. Int Immunol, 26, 47-57. https://doi.org/10.1093/intimm/dxt042
  26. Zhong J, Wang Y, Qiu X, et al (2006). Characterization and expression profile of CMTM3/CKLFSF3. J Biochemistry Molecular Biol, 39, 537-45.